Jeffrey Hatfield was appointed to the Board of Directors (the “Board”) of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) as a Class III director, whose term shall expire in 2017.  Mr. Hatfield was also appointed to serve on the Nominating and Corporate Governance Committee of the Board and the Compensation Committee of the Board.

Mr. Hatfield will receive an annual cash retainer of $35,000, paid in quarterly installments, for his service as a director, an annual cash retainer of $5,000, paid in quarterly installments, for his service as a member of the Compensation Committee of the Board and an annual cash retainer of $3,750, paid in quarterly installments, for his service as a member of the Nominating and Corporate Governance Committee of the Board. He will also be entitled to reimbursement for reasonable travel expenses in connection with attendance at meetings of the Board and Board committees. In connection with his appointment, under the Company’s director compensation policy, the Board approved the grant to Mr. Hatfield of an option to purchase up to 25,000 shares of the Company’s common stock, which will vest in 24 equal installments on each monthly anniversary of the date of grant until fully vested on the 24-month anniversary of the date of grant, provided that he remains a director of the Company on each such vesting date.